de Gregorio, Amelie http://orcid.org/0000-0001-8273-9906
Häberle, Lothar
Fasching, Peter A.
Müller, Volkmar
Schrader, Iris
Lorenz, Ralf
Forstbauer, Helmut
Friedl, Thomas W. P.
Bauer, Emanuel
de Gregorio, Nikolaus
Deniz, Miriam
Fink, Visnja
Bekes, Inga
Andergassen, Ulrich
Schneeweiss, Andreas
Tesch, Hans
Mahner, Sven
Brucker, Sara Y.
Blohmer, Jens-Uwe
Fehm, Tanja N.
Heinrich, Georg
Lato, Krisztian
Beckmann, Matthias W.
Rack, Brigitte
Janni, Wolfgang
Funding for this research was provided by:
Novartis Pharma
AstraZeneca
Chugai
Sanofi Aventis
Lilly Deutschland
Article History
Received: 23 April 2020
Accepted: 1 October 2020
First Online: 23 October 2020
Ethics approval and consent to participate
: The protocol was reviewed and approved by the relevant ethics committees in Germany and conducted in accordance with the Declaration of Helsinki and good clinical practice guidelines. All patients gave written informed consent before entering the study.
: Not applicable.
: AdG: honoraria from Novartis, Roche, Pfizer, Daiichi-Sankyo, Tesaro, and Eisai. PF: honoraria and/or grants from Novartis, Amgen, Pfizer, Eisai, Celgene, Myelo Therapeutics, Merk Sharp & Dohme, Macrogenics, Roche, MSD, Daiichi-Sankyo, TEVA, AstraZeneca, Novartis, Puma, Biontech, Daiichi-Sankyo, and Cepheid. VM: speaker honoraria from Amgen, Astra Zeneca, Celgene, Daiichi-Sankyo, Eisai, Pfizer, Novartis, Roche, Teva, and consultancy honoraria from Genomic Health, Hexal, Roche, Pierre Fabre, Amgen, Novartis, MSD, Daiichi-Sankyo, Eisai, Lilly, Tesaro, and Nektar. Institutional research support from Novartis, Roche, Seattle Genetics, and Genentech. HF: honoraria from Novartis, Roche, Celgene, Astellas Pharma, and Merck. TWPF: honoraria from Novartis. NdG: honoraria from Roche, Tesaro, Amgen, PharmaMar, Astrazeneca, and Clovis. AS: honoraria, grants, personal fees, and non-financial support from Roche, Celgene, AbbVie, Molecular Partner, AstraZeneca, Pfizer, Novartis, MSD, Tesaro, and Lilly. HT: honoraria from Novartis and Roche. SM: research support, honoraria, travel expenses from AstraZeneca, Bayer, Boehringer Ingelheim, Clovis, Eisai, GlaxoSmithKline, Jenapharm, Janssen-Cilag, Medac, MSD, PharmaMar, Roche, Sensor Kinesis, Teva, and Tesaro. JUB: honoraria from Roche, Novartis, and Pfizer. SYB: honoraria from Novartis, Roche, and Pfizer. MWB: MWB’s institution conducts research with funding from Novartis and Pfizer. BR: honoraria from AstraZeneca, Chugai, Lilly, Novartis, Sanofi-Aventis, and Jannssen-Cilag. WJ: honoraria from Sanofi-Aventis, Novartis, and Pfizer. All other authors have no conflict of interest.